| abstract |
The present invention features nitric oxide synthase (NOS) inhibitors, particularly those that selectively inhibit nitric oxide synthase (nNOS) preferably to other NOS isoforms. The NOS inhibitors of the invention alone or in combination with other pharmaceutically active agents can be used to treat or prevent conditions such as, for example, congestion, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache, and migraine headache, with no migraine headache, central post-embolism pain (CPSP), neuropathic pain, caused by morphine / opioid tolerance and hyperalgesia. |